Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144911
Status:
COMPLETED
Last Update Posted:
2016-10-28
First Post:
2005-09-01
Brief Title:
ADVAIR DISKUS Inhaler Fluticasone PropionateSalmeterol Versus SEREVENT DISKUS Inhaler Salmeterol For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations ADVAIR DISKUS Inhaler and SEREVENT DISKUS Inhaler Are Trademarks of the GSK Group of Companies
Sponsor:
Organization:
GlaxoSmithKline
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
740
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE4 |
Observational Models:
Time Perspective List:
Who Masked List: